


CRK12-IN-1

Cat. No.:	HY-145812
CAS No.:	1990479-14-5
Molecular Formula:	C ₂₀ H ₂₆ F ₂ N ₄ O ₃ S ₂
Molecular Weight:	472.57
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CRK12-IN-1 is a potent CRK12 inhibitor. CRK12-IN-1 is extremely potent against <i>T.b. brucei</i> and rapidly cytotoxic, as well as equally potent against <i>T. congolense</i> and <i>T. vivax</i> (EC ₅₀ of 1.3 and 18 nM, respectively) ^[1] .
IC₅₀ & Target	EC ₅₀ : 1.3 nM (<i>T. congolense</i>), 18 nM (<i>T. vivax</i>) ^[1]
In Vitro	CRK12-IN-1 (compound 1) (10 mg/mL; 69 hours) is extremely potent against <i>T.b. brucei</i> and in animal models of <i>T.b. brucei</i> infection, as well as a potent inhibitor of <i>T. congolense</i> (EC ₅₀ of 1.3 and 18 nM, respectively) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CRK12-IN-1 (compound 1) (50 or 10 mg/kg; s.c.; once daily for 4 days) can elicit sterile cure in against <i>T. congolense</i> infected mice, also has the same effect but marginally more efficacious (30 or 3 mg/kg; s.c.; daily, for 4 days) in against <i>T. vivax</i> infected mice ^[1] . CRK12-IN-1 (5 mg/kg, s.c., twice 12 h apart for 4 days) can suppress parasitaemia below the level of detection in <i>T. congolense</i> infected calves, but parasitaemia quickly re-emerges following the cessation of treatment ^[1] . CRK12-IN-1 (10 mg free base/kg; s.c.; for 0.08-8 hours) has 74% of bioavailability with a half-life of about 1 hour in female NMRI mice ^[1] . CRK12-IN-1 (i.m. at 5 mg free base/kg or i.v. at 2.5 mg free base/kg; 0.25-120 hours) has a moderate clearance from the blood and a relatively short half-life (about 1.8 h) in male ruminating Holstein-Friesian, and penetrate tissues beyond the vasculature ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Smith A, et al. Repositioning of a Diaminothiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal Trypanosomiasis [published online ahead of print, 2022 Mar 18]. *J Med Chem.* 2022;10.1021/acs.jmedchem.1c02104.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA